NCT03095781View on ClinicalTrials.gov

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions
Colorectal AdenocarcinomaMetastatic Pancreatic AdenocarcinomaRecurrent Colorectal CarcinomaRecurrent Pancreatic CarcinomaStage III Colorectal CancerStage III Pancreatic CancerStage IIIA Colorectal CancerStage IIIB Colorectal CancerStage IV Colorectal CancerStage IV Pancreatic CancerStage IVA Colorectal CancerStage IVA Pancreatic CancerStage IVB Colorectal CancerStage IVB Pancreatic CancerUnresectable Pancreatic Carcinoma
Interventions
DRUG

XL888

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Exelixis

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER